Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IER2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The immediate early response gene 2 (IER2) also known as ETR101 is a protein with a molecular mass of approximately 30 kDa. Researchers often find IER2 expressed across various tissues including the heart kidney and brain. Being an immediate early gene IER2 rapidly responds to growth factors stress and other stimuli. Its function does not require de novo protein synthesis allowing an immediate response to environmental cues or cellular states.
Biological function summary
IER2 influences cell proliferation and differentiation. It interacts with several signaling pathways indicating its role in controlling cell cycle progression. Scientists have discussed IER2's involvement in cellular stress responses acting independently rather than as part of a larger protein complex. These activities help the protein regulate gene expression temporarily an important element in maintaining cellular homeostasis.
Pathways
IER2 functions within signaling networks essential for mitogenic responses and stress-activated MAPK pathways. It shares pathways with proteins such as c-Fos and c-Jun which are part of the AP-1 transcription factor complex. These connections position IER2 as a participant in pathways that manage cellular responses to external stimuli and internal signals important for cell growth and survival.
Scientists associate IER2 with cancer and neurodegenerative conditions. In cancer IER2 promotes metastasis by influencing cell migration and invasion often through interaction with matrix metalloproteinases. Additionally its dysregulation may contribute to neurodegenerative disorders linking it to proteins involved in neuronal survival and death. Understanding these interactions could provide insight into therapeutic targets for combatting related diseases.
